Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS (December 9, 2024) by Dewpoint Therapeutics. Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of >97% of ALS patients. Mitsubishi Tanabe Pharma Corporation obtains